Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604541 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL615910 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL15727302 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2CTSKCTSSCTSLNFKB1 | |
| SCHEMBL15727246 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL23736344 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL17884308 | 0.88 | PPARA (0.42) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL614209 | 0.87 | PPARA (0.53) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL1430675 | 0.87 | PPARA (0.53) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL614208 | 0.87 | PPARA (0.53) | SMN1; SMN2PPARACTSKCTSSCTSL | |
| SCHEMBL7541004 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKCTSSCTSLNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| CN-107973809-B | Macrocyclic compounds as factor XIA inhibitors | 百时美施贵宝公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2011100402-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| WO-2011042399-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082294-A1 | NOVEL BICYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-07 | — | — | US | disclosed |
| EP-1664092-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885PPARA 4860/4885CTSK 85/4885 |
| US-20110082294-A1 | NOVEL BICYCLIC COMPOUNDS | CCR2, CCR3, CCR1 | SMN1; SMN2 4525/4885PPARA 534/4885CTSK 2628/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885PPARA 4860/4885CTSK 85/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | SMN1; SMN2 271/4885PPARA 4669/4885CTSK 1101/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | SMN1; SMN2 301/4885PPARA 3192/4885CTSK 943/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | SMN1; SMN2 2726/4885PPARA 3658/4885CTSK 16/4885 |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | SMN1; SMN2 3511/4885PPARA 3540/4885CTSK 130/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885PPARA 4860/4885CTSK 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.